Circulating monocytes and atherogenesis: From animal experiments to human studies

Thrombosis and Haemostasis

Volumn 104, Issue 2, 2010, Pages 191-193

  Shantsila, Eduard ^a   Devitt, Andrew ^b   Lip, Gregory Y H ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EDITORIAL; HUMAN; HUMAN CELL; IMMUNE SYSTEM; INNATE IMMUNITY; LIPID METABOLISM; MONOCYTE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR;

ANIMALS; ANTIGENS, CD; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; LIPID METABOLISM; MONOCYTES; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 77955455259     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-03-0176     Document Type: Editorial

References (27)

1. Eijgelaar WJ, Heeneman S, Daemen MJ. The vulnerable patient: refocusing on the plaque? Thromb Haemost 2009; 102: 231-239.
2. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol 2006; 47 (8 Suppl): C7-12.
3. Santilli F, Davì G. Thrombin as a common downstream target blocking both platelet and monocyte activation. Thromb Haemost 2009; 101: 220-221.
4. Shantsila E, Lip GY. The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet aggregates and novel mechanisms. Thromb Haemost 2009; 102: 916-924.
5. Weber C. Frontiers of vascular biology: mechanisms of inflammation and immunoregulation during arterial remodelling. Thromb Haemost 2009; 102: 188-190.
6. Choudhury RP, Lee JM, Greaves DR. Mechanisms of disease: Macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis. Nat Clin Pract Cardiovasc Med 2005; 2: 309-315.
7. Murphy JE, Tedbury PR, Homer-Vanniasinkam S, et al. Biochemistry and cell biology of mammalian scavenger receptors. Atherosclerosis 2005; 182:1-15.
8. Kapinsky M, Torzewski M, Büchler C, et al. Enzymatically degraded LDL preferentially binds to CD14(high) CD16(+) monocytes and induces foam cell formation mediated only in part by the class B scavenger-receptor CD36. Arterioscler Thromb Vasc Biol 2001; 21: 1004-1010.
9. Nozaki S, Kashiwagi H, Yamashita S, et al. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J Clin Invest 1995; 96: 1859-1865.
10. Horne BD, Anderson JL, John JM, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol 2005; 45: 1638-1643.
11. Ohashi K, Burkart V, Flohe S, et al. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164: 558-561.
12. Soehnlein O, Zernecke A, Weber C. Neutrophils launch monocyte extravasation by release of granule proteins. Thromb Haemost 2009; 102: 198-205.
13. Schuett H, Luchtefeld M, Grothusen C, et al. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009; 102: 215-222.
14. Hanriot D, Bello G, Ropars A, et al. C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes. Thromb Haemost 2008; 99: 558-569.
15. Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117: 195-205.
16. Tacke F, Alvarez D, Kaplan TJ, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007; 117: 185-194.
17. Veillard NR, Steffens S, Pelli G, et al. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation 2005; 112: 870-878.
18. Combadière C, Potteaux S, Rodero M, et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008; 117: 1649-1657.
19. Wu H, Gower RM, Wang H, et al. Functional role of CD11c+ monocytes in atherogenesis associated with hypercholesterolemia. Circulation 2009; 119: 2708-2717.
20. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009; 27: 669-692.
21. Rothe G, Herr AS, Stöhr J, et al. A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. Atherosclerosis 1999; 144: 251-261.
22. Schlitt A, Heine GH, Blankenberg S, et al. CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost 2004; 92: 419-424.
23. Mosig S, Rennert K, Krause S, et al. Different functions of monocyte subsets in familial hypercholesterolemia: potential function of CD14+ CD16+ monocytes in detoxification of oxidized LDL. FASEB J 2009; 23: 866-874.
24. Dresel HA, Via DP, Stohr M, et al. Observations on leukocytes from patients with severe familial hypercholesterolemia. Arteriosclerosis 1986; 6: 259-264.
25. Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007; 317: 666-670.
26. Soehnlein O, Zernecke A, Weber C. Neutrophils launch monocyte extravasation by release of granule proteins. Thromb Haemost 2009; 102: 198-205.
27. Hristov M, Leyendecker T, Schuhmann C, et al. Circulating monocyte subsets and cardiovascular risk factors in coronary artery disease. Thromb Haemost 2010; 104: 412-414.